SS-31 (Elamipretide) Mechanism of Action

Introduction

SS-31 (elamipretide; D-Arg-Dmt-Lys-Phe-NH2) is a synthetic tetrapeptide whose reported mechanism of action centers on selective, reversible binding to cardiolipin at the inner mitochondrial membrane (IMM). Published research has characterized this interaction as modulating the cytochrome c/cardiolipin complex, influencing electron transport chain (ETC) architecture, and altering mitochondrial membrane surface electrostatics. This article summarizes the mechanistic findings reported in the primary peer-reviewed literature; further structural and regulatory context is covered in the SS-31 research overview.

Primary Target: Cardiolipin at the Inner Mitochondrial Membrane

The defining pharmacological interaction of SS-31 is its reported binding to cardiolipin, a bis-phosphatidylglycerol phospholipid that constitutes approximately 20% of IMM phospholipid mass and is functionally required for the structural organization of ETC supercomplexes and cristae architecture. SS-31 accumulates at the IMM in a manner reported to be independent of mitochondrial membrane potential, distinguishing it from cationic lipophilic compounds such as triphenylphosphonium-conjugated antioxidants [1].

Zhao and colleagues reported in 2004 that the alternating aromatic-cationic motif of SS peptides confers the structural basis for this targeting: basic residues (D-arginine and lysine; formal charge +3) mediate electrostatic attraction to the negatively charged cardiolipin head groups, while aromatic residues (dimethyltyrosine and phenylalanine) participate in hydrophobic and pi-electron interactions with the acyl chains of the phospholipid bilayer [1].

Biophysical characterization by Mitchell and colleagues (2020) using fluorescence spectroscopy and zeta-potential measurements confirmed that SS-31 partitions into the interfacial region of cardiolipin-containing membranes. The authors reported that the degree of membrane association correlated with membrane surface charge density, consistent with an electrostatic mechanism, and that SS-31 measurably modulated surface electrostatics of both model lipid bilayers and mitochondrial membranes isolated from cardiac tissue [2].

Reported Molecular Interactions: The Cytochrome c/Cardiolipin Complex

A principal mechanism proposed in the published literature involves SS-31's modulation of the cardiolipin-cytochrome c interaction at the IMM surface. Cytochrome c is a soluble heme protein that normally functions as an electron carrier between Complexes III and IV of the ETC. Under oxidative stress conditions, cardiolipin peroxidation has been reported to convert cytochrome c into a cardiolipin peroxidase — an enzymatic activity that further amplifies reactive oxygen species (ROS) production and cardiolipin degradation, and that can trigger cytochrome c release into the cytosol as an apoptosis-initiating event [3].

Birk, Chao, Bracken, Warren, and Szeto (2014) reported that SS-31 binding to cardiolipin inhibited this peroxidase activity while preserving cytochrome c's electron-carrier function. The authors proposed that SS-31 interacts with the cardiolipin-cytochrome c complex by occupying specific interaction sites on the cardiolipin acyl chains, thereby maintaining the structural conformation of cytochrome c's heme iron in its electron-carrier rather than peroxidase configuration [3]. The study also reported that treatment with SS-31 in cardiac mitochondria was associated with preservation of cristae ultrastructure under stress conditions, consistent with cardiolipin's structural role in IMM architecture.

Szeto (2014) summarized this model in a comprehensive review, describing SS-31 as the "first-in-class cardiolipin-protective compound," a characterization based on its reported ability to selectively stabilize cardiolipin against peroxidation without altering mitochondrial membrane potential or compromising ETC function in non-stressed conditions [4].

Reported Downstream Effects on Electron Transport and ATP Synthesis

Published studies have reported associations between SS-31 treatment and alterations in ETC function in multiple experimental models, with the cardiolipin-cytochrome c interaction proposed as the upstream node.

Birk and colleagues (2014) reported that in isolated cardiac mitochondria, SS-31 was associated with an observed optimization of electron flux through the cytochrome c/cardiolipin segment of the ETC, with increased state 3 (ADP-stimulated) respiration and ATP production rates compared to untreated controls under conditions of oxidative stress [3].

In ex vivo human myocardial tissue, Chatfield and colleagues (2019) reported that elamipretide treatment of freshly explanted failing human ventricular tissue was associated with significant increases in mitochondrial oxygen flux, Complex I and Complex IV enzymatic activities, and supercomplex-associated Complex IV activity compared with vehicle-treated tissue from the same hearts. These observations were reported in JACC: Basic to Translational Science and represented the first evidence of the compound's reported effects in failing human cardiac mitochondria [5].

At the protein-interaction level, a 2020 study published in the Proceedings of the National Academy of Sciences applied chemical cross-linking combined with mass spectrometry to characterize the SS-31 interactome within intact mitochondria. The authors reported that SS-31's principal identified binding partners clustered around ATP synthase (Complex V) and proteins of the 2-oxoglutarate metabolic pathway, with cardiolipin serving as the likely anchor mediating these protein-level associations. The authors interpreted these findings as consistent with a mechanism in which cardiolipin binding by SS-31 reorganizes the local protein environment of the IMM to support more efficient ATP synthesis [6].

Membrane Electrostatics and Structural Consequences

Beyond discrete protein-binding interactions, Mitchell and colleagues (2020) proposed that SS-31's modulation of IMM surface electrostatics may constitute an additional mechanistic layer. By altering the surface charge of the IMM, SS-31 could in principle influence the distribution of divalent cations (including Ca2+ and Mg2+), the activity of other positively charged proteins that interact with the IMM, and the biophysical properties of the bilayer itself [2]. The authors noted that this electrostatically driven mechanism could help explain why SS-31 displays apparent effects across multiple ETC complexes and functional outcomes, rather than through a single-protein binding event. This IMM-surface approach is mechanistically distinct from, though broadly complementary to, the NAD+ mechanism of action, which operates upstream of the ETC through sirtuin and PARP signaling pathways. The SS-31 product page provides batch-specific purity documentation for research applications.

Areas of Ongoing Mechanistic Investigation

The mechanistic literature on SS-31 has expanded considerably since the original 2004 characterization, and several questions are the subject of active investigation. The precise stoichiometry of SS-31's interaction with cardiolipin under physiological conditions in intact cells has not been definitively established. The relative contributions of the peroxidase-inhibition mechanism, the protein-reorganization mechanism, and the electrostatic-modulation mechanism to observed experimental outcomes remain under investigation in unified experimental systems.

The 2020 PNAS interactome study identified specific protein contacts within isolated mitochondria; subsequent work is extending these observations to in vivo conditions to characterize compartmental dynamics, membrane trafficking, and the kinetics of SS-31 accumulation at the IMM [7]. The molecular basis for differential response across genetic subtypes of primary mitochondrial myopathy observed in the MMPOWER-3 trial — a pre-specified subgroup analysis reported numerically greater response among participants with nuclear DNA mutations versus mitochondrial DNA mutations — is among the mechanistic hypotheses under active investigation in the field.

References

1. Zhao K, Zhao G-M, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-34690. PMID: 15178689. DOI: 10.1074/jbc.M402999200

2. Mitchell W, Ng EA, Tamucci JD, Boyd KJ, Sathappa M, Coscia A, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295(21):7452-7469. PMID: 32321821. PMC: PMC7247319. DOI: 10.1074/jbc.RA119.012094

3. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017-2028. PMID: 24134698. DOI: 10.1111/bph.12468

4. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. PMID: 24117165. DOI: 10.1111/bph.12461

5. Chatfield KC, Sparagna GC, Chau S, Phillips EK, Ambardekar AV, Aftab M, et al. Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. 2019;4(2):147-157. PMID: 31061916. PMC: PMC6488757. DOI: 10.1016/j.jacbts.2018.12.005

6. Chavez JD, Tang X, Campbell MD, Bhatt U, Grob MS, Sullivan BN, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci USA. 2020;117(26):15363-15373. PMC: PMC7334473. DOI: 10.1073/pnas.2002250117

7. Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(1):e42-e54. PMC: PMC10382259. DOI: 10.1212/WNL.0000000000207402